Go Deep
Concord Biotech Limited
Concord Biotech Limited Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Sep 2026 | 21,163 | 52.9 | 7.95 | 0.00 | 1,532.40 |
| Sep 2026 | 21,388 | 51.6 | 7.78 | 0.00 | 1,499.50 |
| Sep 2026 | 22,117 | 47.9 | 7.22 | 0.00 | 1,392.70 |
| Sep 2026 | 22,117 | 47.9 | 7.22 | 0.00 | 1,392.70 |
| Sep 2026 | 22,117 | 47.9 | 7.22 | 0.00 | 1,392.70 |
| Oct 2026 | 20,647 | 47.4 | 7.13 | 0.00 | 1,374.10 |
| Oct 2026 | 20,053 | 46.9 | 7.06 | 0.00 | 1,361.40 |
Concord Biotech Limited Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 2,574,890,000.0 | 3,260,796,000.0 | 2,777,660,000.0 | 2,470,575,000.0 |
| Net Profit | 576,969,000.0 | 887,905,000.0 | 636,415,000.0 | 630,628,000.0 |
| EPS | 8.5 | 8.5 | 6.1 | 6.0 |
Concord Biotech Limited Revenue & Profit: Last 5 Years
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Revenue | 10,463,581,000.0 | 11,798,178,000.0 | 9,980,573,000.0 | 8,306,322,000.0 | — |
| Net Profit | 2,609,059,000.0 | 3,716,423,000.0 | 3,081,032,000.0 | 2,400,857,000.0 | — |
| EPS | 24.8 | 35.5 | 29.4 | 22.9 | — |
Concord Biotech Limited Balance Sheet
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Total Assets | 22,347,271,000.0 | 20,342,515,000.0 | 17,007,085,000.0 | 15,139,818,000.0 | — |
| Total Liabilities | 2,195,891,000.0 | 2,215,340,000.0 | 1,740,630,000.0 | 2,239,793,000.0 | — |
| Total Equity | 20,170,613,000.0 | 18,127,175,000.0 | 15,266,455,000.0 | 12,900,025,000.0 | — |
Owes vs Owns
Concord Biotech Limited owed ₹0.10 for every ₹1 it owned in Mar 2026, down from ₹0.15 in Mar 2023.
| Period | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Owes vs Owns | 0.10× | 0.11× | 0.10× | 0.15× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Concord Biotech Limited Assets & Liabilities Breakdown (₹ Cr)
What it owns — Mar 2026
Cash & short-term investments 18.2%Receivables 20.6%Inventory 14.6%Fixed assets (tangible) 39.2%Other assets 7.2%
How it's funded — Mar 2026
Payables 4.6%Other liabilities 5.2%Shareholders' equity 90.2%
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 406.6 | 334.6 | 285.5 | 181.1 |
| Receivables | 460.2 | 521.7 | 349.6 | 273.8 |
| Inventory | 326.4 | 239.7 | 208.0 | 212.3 |
| Fixed assets (tangible) | 875.7 | 851.7 | 794.5 | 773.1 |
| Intangible assets | 1.8 | 1.1 | 0.3 | 0.2 |
| Long-term investments | 3.6 | 0.7 | 2.1 | 0.0 |
| Other assets | 160.4 | 84.8 | 60.8 | 73.5 |
| Liabilities & equity | ||||
| Short-term debt | 0.0 | 0.4 | 6.2 | 25.0 |
| Long-term debt | 1.4 | 0.0 | 0.0 | 6.2 |
| Payables | 101.9 | 113.0 | 94.4 | 93.8 |
| Other liabilities | 116.2 | 108.1 | 73.4 | 98.9 |
| Shareholders' equity | 2,015.1 | 1,812.7 | 1,526.6 | 1,290.0 |
| Net tangible assets | 2,015.2 | 1,811.6 | 1,526.3 | 1,289.8 |
Concord Biotech Limited Cash Flow
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Operating Activities | 2,668,813,000.0 | 2,445,169,000.0 | 2,654,671,000.0 | 2,460,018,000.0 | — |
| Investing Activities | -1,427,236,000.0 | -1,599,865,000.0 | -1,546,093,000.0 | -1,579,501,000.0 | — |
| Financing Activities | -1,128,762,000.0 | -987,680,000.0 | -992,149,000.0 | -852,194,000.0 | — |